(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 5 July 2007 (05.07.2007)

(10) International Publication Number WO 2007/076537 A3

(51) International Patent Classification:

C12N 15/09 (2006.01) A61K 38/48 (2006.01) C12P 21/06 (2006.01) A61K 38/00 (2006.01) C12N 15/00 (2006.01) C07K 4/00 (2006.01)

(21) International Application Number:

PCT/US2006/062723

(22) International Filing Date:

29 December 2006 (29.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/754,731 29 December 2005 (29.12.2005)

(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): BAJAJ, Paul, S. [US/US]; 704 West Holme Ave., Los Angeles, CA 90024 (US).
- (74) Agents: HODGES, Robert, A. et al.; Needle & Rosenberg, P.C., Suite 1000, 999 Peachtree Street, Atlanta, GA 30309-3915 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 14 February 2008



International application No.

PCT/US06/62723

A. CLASSIFICATION OF SUBJECT MATTER IPC: C12N 15/09(2006.01);C12P 21/06(2006.01);C12 4/00(2006.01)	N 15/00(2006.01);A61K 38/48(2006.01),	38/00(2006.01);C07K		
USPC: 435/69.1,320.1;424/94.64;514/12;530/300 According to International Patent Classification (IPC) or to both na	tional classification and IPC			
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/69.1,320.1;424/94.64;514/12;530/300				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category * Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.		
X US 6,103,499 (MARKLAND et al.) 15 August 2000	(15.08.200), abstract; column 10, lines	1,3,8		
Y 55-58; column 14, lines 31-33, 56-60.		2,4,5,8,22		
Y CHAND et al. Structure-funtions analysis of the reac of human tissue factor pathway inhibitor-2. The Journ 2004, Vol 279, No.17, pages 17500-17507, especiall	arnal of Biological Chemistry. 23 April			
Y US 2004/0229312 A1 (BOUGLELERET et al.) 18 N page 8, paragraph 73.	3 November 2004 (18.11.2004), especially 2,4,5,7			
Y SCHMIDT et al. Crystal Struture of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in comples with trypsin. The Journal of Chemistry. 29 July 2005, Vol 280, No. 30, 27832-27838, especially pages 27833, left column, lines 14-16, 27837, right column, last paragraph.		2,4,5,7		
Further documents are listed in the continuation of Box C.	See patent family annex.			
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being			
"O" document referring to an oral disclosure, use, exhibition or other means	obvious to a person skilled in the art			
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent far			
Date of the actual completion of the international search	Date of mailing of the international search report			
19 November 2007 (19.11.2007) Name and mailing address of the ISA/US	Allazo File 2007			
Mail Stop PCT, Attn: ISA/US	Causal toul			
Commissioner for Patents P.O. Box 1450	Maury Audet			
Alexandria, Virginia 22313-1450	Telephone No. 571-272-1600 <i>U</i>	10		
Facsimile No. (571) 273-3201 form PCT/ISA/210 (second sheet) (April 2005)	L			

International application No.

PCT/US06/62723

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
	onal Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet			
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4. Remark on P	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-8 and 22 rotest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.			

Form PCT/ISA/210 (continuation of first sheet(2)) (April 2005)

International application No. PCT/US06/62723

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Υ	US 2005/0222023 A1 (HAUSER et al.) 6 October 2005 (06.10.2005), abstract, Table 4.	22		

	International application N
INTERNATIONAL SEARCH REPORT	PCT/US06/62723

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contain the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under the PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional fees must be paid.

Group I, claims 1-8 and 22 are drawn to a polypeptide comprising SEQ ID NO:1 with one or more amino acid mutations.

Group II, claim 9 is drawn to a nucleic acid encoding the polypeptide.

Group III, claims 10 -19 and 24 are drawn to method of treating a subject in need of inhibition of a plasmin activity by administering to the subject the polypeptide.

Group IV, claim 20 is drawn to a method of identifying a plasmin inhibitor.

Group V, claim 21 is drawn to a method of inhibiting plasmin in a subject in need by administering to the subject the nucleic acid encoding the polypeptide.

Group VI, claim 23 is drawn to a transgenic animal comprising the nucleic acid encoding the polypeptide.

The International Searching Authority considers that the international applications does not comply with the requirement of unity of invention (PCT Rule 13.1, 13.2 and 13.3) for the reason indicated below:

The inventions are linked by the technical feature of mutations in the domain I of TFPI-2 that is plasmin inhibitor. However, this is not special because it does not constitute an advance over the prior art. Markland et al. (US6,103,499) teach a plasmin inhibitor derived from Human TFPI-2 domain 1 that contains substitutions Y11T, L17R, L18F, L19D, and R31E (column 10, lines 55-60).

Furthermore, each Group involves methods not required by the other.

Group I, a first product, requires substitutions in positions 10, 11, 16, 17 and 46 of the polypeptide of SEQ NO: 1, not required by any other group.

Group II, a second product, requires a nucleic acid, not required by any other group.

Group III, a first method, requires multiple plasmin inhibitor applications, not required by any other group.

Group IV, a second method, requires modeling a crystal structure of plasmin, not required by any other group.

International application No. PCT/US06/62723

Group V, a third method, requires the nucleic acid to the protein directed to inhibiting plasmin, not required by any other group. Group VI, a third product, requires a transgenic animal, not required by any other group.	
Continuation of B. FIELDS SEARCHED Item 3: USPAT, US-PGPUB, BIOSIS, CAPLUS, MEDLINE Search terms: KD1, Kunitz domain, plasmin, inhibitor	